Table 1

Characteristics of patients divided by islet Ab and islet-reactive T-cell positivity

Patient category (N = 23)
Ab−T−Ab+T−Ab−T+Ab+T+Unknown*
Patients, n (%)6 (26)2 (9)7 (30)5 (22)3 (13)
Age (years) (median ± SE)53 ± 460 ± 157 ± 558 ± 349 ± 4
Sex (%)
 Males17100718067
 Females830292033
BMI (kg/m2) (median ± SE)
 Baseline 43 ± 234 ± 236 ± 227 ± 132 ± 2
 Study end43 ± 234 ± 134 ± 229 ± 231 ± 2
Length of follow-up (months) (median ± SE)36 ± 423 ± 1415 ± 436 ± 433 ± 6
Baseline FCP (ng/mL) (median ± SE)5 ± 0.45 ± 0.23 ± 0.43 ± 0.24 ± 1
Baseline glucagon-SCP (ng/mL) (median ± SE)9 ± 19 ± 25 ± 15 ± 0.47 ± 2
Race (%)
 Caucasian83501006067
 African American000200
 Asian175002033
T2D disease duration (%)
 <1 year1710014200
 1–2 years330434067
 >2 years500434033
 Mean ± SD (years)2 ± 20.3 ± 0.13 ± 22 ± 23 ± 2
 Median ± SE (years)3 ± 10.3 ± 0.12 ± 12 ± 12 ± 1
Positivity (%)
 GADA+050010033
 IA-2+010002033
 Islet T cells+0010010067
  • *Autoimmune positive 1 time point only.